A phase I/II dose-escalation-trial of recombinant human histone H1.3 in subjects with relapsed or refractory AML

6618 Background: A central issue in the therapy of patients with AML concerns the high relapse and failure rates especially in the elderly population. Most of the efforts on more effective treatmen...